- JNJ dividends annualize to $5.36 per share, with a forward yield of 1.98% at a $270.24 share price.
- Operating cash flow of $24.53 billion covered $12.38 billion in 2025 dividends, supporting payout safety.
- The planned mid-2027 DePuy Synthes separation could alter the post-spinoff dividend profile.
Johnson & Johnson (NYSE: JNJ) remains one of healthcare’s most dependable dividend-growth stocks. Its $1.34 quarterly payout, payable September 8 to eligible shareholders, annualizes to $5.36 per share.
At a $270.24 share price, JNJ dividends offer a forward yield of 1.98%. The low yield reflects a sharp rally that has made income-focused buyers more selective.
Dividend safety remains the main attraction
JNJ has delivered 64 consecutive annual dividend increases, placing it among the market’s most durable income compounders. Its latest increase was 3.1%, from $1.30 to $1.34 per quarter.
The forward dividend equals roughly 48% of estimated 2026 earnings, based on consensus EPS near $11.05. That payout ratio leaves capital for research, acquisitions, debt service and future dividend raises.
Cash generation also supports the JNJ dividend. The company produced operating cash flow of $24.53 billion versus $12.38 billion in dividends during 2025 and expects nearly $21 billion in 2026 free cash flow.
Drug portfolio helps offset Stelara pressure
Biosimilar competition is reducing sales of immunology blockbuster STELARA, but JNJ’s broader drug portfolio is compensating. Key growth treatments include DARZALEX revenue growth of 22.5% and TREMFYA growth of 68.3%, alongside continued expansion for CARVYKTI.
Management has raised its 2026 adjusted EPS outlook to $11.65. The diversified portfolio supports the case for continued JNJ dividend growth beyond any single medicine.
DePuy Synthes spinoff is the key income risk
The main issue is JNJ’s planned mid-2027 separation of DePuy Synthes. JNJ preserved its dividend-growth record through the Kenvue separation, but the new transaction could result in a lower parent dividend, a new dividend at the separated business, or both.
Investors should not assume the current $5.36 annual payout will transfer unchanged across the post-separation companies. Dividend-policy announcements, pro-forma cash-flow guidance and debt allocations will be important as the deal approaches.
Valuation limits starting income
JNJ trades near its 52-week high of $276.47 and at a trailing P/E of about 31.4. Its yield has fallen below its 2.72% five-year average.
Existing shareholders may continue to view JNJ as a hold for growing qualified-dividend income. New investors may prefer to build positions gradually rather than chase the shares near record levels.
